PRTC Puretech Health
- 27.520
- 0.0000.00%
Puretech Health News
PureTech Founded Entity Seaport Therapeutics Presents Data From Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX. SPT-300 has been shown to retain the activity and potency of natural allopregnanolone in an oral form and has the potential to capture the breadth of the naturally occurring neurosteroid, which is believed to have significant therapeutic potential in a range of mood and anxiety disorders, including anxious depression.
PureTech Health: Share Capital and Pipeline Update
PureTech Health Plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript
Earnings Call Summary | Puretech Health(PRTC.US) Q4 2023 Earnings Conference
The following is a summary of the PureTech Health Plc (PRTC) Q4 2023 Earnings Call Transcript:Financial Performance:PureTech Health ended 2023 with cash, cash equivalents and short-term investments of
PureTech Health Plc (PRTC) Q4 2023 Earnings Call Transcript
PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript
Express News | PureTech Health FY 2023 GAAP EPS $(0.24) Beats $(0.93) Estimate, Sales $3.330M Down From $15.618M YoY
Press Release: PureTech Announces Annual Results -44-
On May 9, 2022, the Group announced the commencement of a $50,000 share repurchase program (the "Program") of its ordinary shares of one pence each. In February 2024, the Group completed the Program a
PureTech Announces Annual Results for Year Ended December 31, 2023
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024.
PureTech Health Reports Strong 2023 Financial Position
Earnings Flash (PRTC.L) PURETECH HEALTH Reports FY23 Revenue $3.3M
02:13 AM EDT, 04/25/2024 (MT Newswires) -- Earnings Flash (PRTC.L) PURETECH HEALTH Reports FY23 Revenue $3.3M
Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY24 Loss $-0.24
02:13 AM EDT, 04/25/2024 (MT Newswires) -- Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY24 Loss $-0.24
PureTech Health Schedules Annual Financial Results Release
Express News | PureTech Completes Enrollment In Phase 2b ELEVATE IPF Trial Of LYT-100 (Deupirfenidone) In Idiopathic Pulmonary Fibrosis; Topline Results Expected In Q4 Of 2024
Express News | PureTech's LYT-200 Secures Receives FDA Fast Track Designation For Head And Neck Cancers
PureTech Health Debuts Seaport Therapeutics and Reshuffles Leadership
Express News | PureTech Launches Seaport Therapeutics With $100M Oversubscribed Series A; Daphne Zohar Steps Down To Lead Seaport; Bharatt Chowrira Appointed New CEO
PureTech Health CEO Steps Down; Successor Named
PureTech Health (PRTC.L) on Tuesday said founding Chief Executive Officer Daphne Zohar resigned from the role with immediate effect to become CEO of the newly created entity of the group, Seaport Ther
Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)
PureTech Announces $100M Capital Return Through Tender Offer
PureTech Health Announces $100 Million Shareholder Return
Analysis
Price Target
No Data
